PPARδ agonist 9
PPARδ agonist 9 structure
|
Common Name | PPARδ agonist 9 | ||
|---|---|---|---|---|
| CAS Number | 928023-21-6 | Molecular Weight | 569.04 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C26H28ClF3N4O3S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of PPARδ agonist 9PPARδ agonist 9 (compound 21) is a PPARδ agonist (EC50: 3.6 nM). PPARδ agonist 9 has in vivo efficacy, reducing serum levels of MCP-1 in mice and significantly inhibiting atherosclerosis progression in the LDLr-KO model (inhibition rate: 50-60%)[1]. |
| Name | PPARδ agonist 9 |
|---|
| Description | PPARδ agonist 9 (compound 21) is a PPARδ agonist (EC50: 3.6 nM). PPARδ agonist 9 has in vivo efficacy, reducing serum levels of MCP-1 in mice and significantly inhibiting atherosclerosis progression in the LDLr-KO model (inhibition rate: 50-60%)[1]. |
|---|---|
| Related Catalog | |
| Target |
EC50:3.6 nM (PPARδ)[1] |
| References |
| Molecular Formula | C26H28ClF3N4O3S |
|---|---|
| Molecular Weight | 569.04 |